OLD National Bancorp IN Invests $289,000 in Repligen Co. (NASDAQ:RGEN)

OLD National Bancorp IN purchased a new position in shares of Repligen Co. (NASDAQ:RGEN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,609 shares of the biotechnology company’s stock, valued at approximately $289,000.

Several other large investors have also modified their holdings of RGEN. Parnassus Investments LLC purchased a new stake in shares of Repligen during the third quarter worth approximately $87,475,000. Allspring Global Investments Holdings LLC purchased a new position in Repligen in the third quarter worth $41,540,000. Artisan Partners Limited Partnership raised its position in Repligen by 11.3% in the third quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock worth $247,558,000 after acquiring an additional 157,807 shares in the last quarter. Bank of New York Mellon Corp raised its position in Repligen by 13.0% in the third quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock worth $190,117,000 after acquiring an additional 137,220 shares in the last quarter. Finally, Artemis Investment Management LLP purchased a new position in Repligen in the fourth quarter worth $22,552,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on RGEN. Stifel Nicolaus increased their price objective on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. KeyCorp upped their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average price target of $196.70.

Repligen Stock Down 1.3 %

RGEN opened at $165.66 on Friday. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. The firm has a market cap of $9.25 billion, a P/E ratio of 230.09, a PEG ratio of 5.50 and a beta of 1.02. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The business’s fifty day simple moving average is $185.05 and its 200 day simple moving average is $173.47.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm had revenue of $155.74 million for the quarter, compared to analyst estimates of $155.38 million. During the same period last year, the company earned $0.68 EPS. The firm’s quarterly revenue was down 16.6% on a year-over-year basis. As a group, equities research analysts anticipate that Repligen Co. will post 1.46 EPS for the current fiscal year.

Insider Transactions at Repligen

In other news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares in the company, valued at approximately $36,575,562.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now owns 24,260 shares in the company, valued at $4,699,889.80. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock worth $5,039,532 in the last three months. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.